2019
Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research And Treatment 2019, 176: 303-310. PMID: 31004299, DOI: 10.1007/s10549-019-05238-4.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerLocal-regional recurrenceDisease-free survivalEffective anti-HER2 therapyLRR-free survivalAnti-HER2 therapyBreast-conserving surgeryBreast cancerRadiation therapySystemic therapyHormone receptor-positive tumorsProspective multi-institutional studyHER2-negative diseaseHER2-positive diseaseNegative axillary nodesEffective systemic therapyProspective multicenter trialEarly-stage patientsKaplan-Meier methodReceptor-positive tumorsHER2-positive tumorsMulti-institutional studyFuture investigational effortsAdjuvant trastuzumabProtocol therapy
2016
Randomized trial of a physical activity intervention in women with metastatic breast cancer
Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer 2016, 122: 1169-1177. PMID: 26872302, DOI: 10.1002/cncr.29899.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalExercise TherapyFemaleFollow-Up StudiesHumansMastectomy, SegmentalMiddle AgedNeoplasm InvasivenessNeoplasm StagingPhysical FitnessQuality of LifeRadiotherapy, AdjuvantReference ValuesSurvival AnalysisTreatment OutcomeUnited StatesConceptsMetastatic breast cancerEarly-stage breast cancerExercise interventionBreast cancerPhysical functioningLife Questionnaire-Core 30 questionnaireModerate-intensity aerobic exercisePhysical Activity Recall interviewModerate-intensity exercise interventionAdvanced breast cancerPhysical activity interventionsTime of enrollmentWait-list control groupQuality of lifeMetastatic diseaseCancer QualityMedian ageIntervention armMedian timeActivity interventionsAerobic exerciseWeekly exerciseTreadmill testFunctional capacityNonsignificant increaseTrends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Research And Treatment 2016, 155: 569-578. PMID: 26868124, DOI: 10.1007/s10549-016-3707-1.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryUse of mastectomyBreast cancer patientsInitial mastectomyBilateral mastectomyBreast cancerDefinitive surgeryInitial surgeryCancer patientsNational Comprehensive Cancer Network centersSmall node-negative breast cancersStage I breast cancer patientsNode-negative breast cancerStage I breast cancerRisk breast cancerSubstantial institutional variationProportion of patientsProspective cohort studyUS academic centersI breast cancerType of surgeryLonger median timeChoice of surgeryEquivalent survival outcomesSignificant institutional variation
2015
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H, Members P, André F, Baselga J, Bergh J, Bonnefoi H, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Galimberti V, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes D, Huober J, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne C, Partridge A, de la Peña L, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Thürlimann B, Toi M, Tutt A, Viale G, von Minckwitz G, Watanabe T, Whelan T, Winer E, Xu B. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals Of Oncology 2015, 26: 1533-1546. PMID: 25939896, PMCID: PMC4511219, DOI: 10.1093/annonc/mdv221.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAxillaBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularChemotherapy, AdjuvantFemaleHumansLymph Node ExcisionMastectomyMastectomy, SegmentalNeoplasm StagingPlatinum CompoundsPractice Guidelines as TopicRadiotherapy, AdjuvantReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTamoxifenTaxoidsTrastuzumabConceptsEarly breast cancerLuminal diseaseBreast cancerSt Gallen International Breast Cancer ConferenceSt Gallen International Expert ConsensusNew breast cancer casesPanel recommendationsEndocrine-responsive diseaseHER2-positive diseaseOvarian function suppressionNode-positive diseaseBreast cancer deathsER-negative diseaseTreatment of patientsAnnals of OncologyNode-negative cancersPremature ovarian failureBreast cancer casesSubstantial new evidenceInternational expert consensusPremenopausal patientsSimplified regimenAdjuvant therapyAxillary dissectionPremenopausal women
2013
Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal Of Clinical Oncology 2013, 31: 2382-2387. PMID: 23690420, PMCID: PMC3691356, DOI: 10.1200/jco.2012.45.2615.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioRadiotherapy, AdjuvantReceptors, EstrogenTamoxifenTime FactorsTreatment OutcomeConceptsBreast cancer-specific survivalEarly-stage breast cancerCancer-specific survivalOverall survivalBreast cancerRadiation therapyRegional recurrenceDistant metastasisER-positive early-stage breast cancerDistant disease-free survivalWomen age 70 yearsEstrogen receptor-positive breast carcinomasFrequency of mastectomyTen-year OSAdjuvant radiation therapyPrimary end pointDisease-free survivalEarly breast cancerAge 70 yearsBreast-conserving surgeryBreast preservationCALGB 9343Locoregional recurrenceTAM groupLocal recurrenceRacial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care?
Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care? Health Services Research 2013, 48: 1669-1683. PMID: 23663229, PMCID: PMC3796107, DOI: 10.1111/1475-6773.12063.Peer-Reviewed Original ResearchConceptsTreatment delayBreast cancerTimely adjuvant therapyEnd Results (SEER) dataMultivariable logistic regressionEthnic differencesRace/ethnicityAdjuvant chemotherapyAdjuvant therapyMedicare claimsSurgical careHigher oddsOlder womenHispanic womenStage IHospitalLogistic regressionRacial disparitiesWomenPatientsBlack womenCancerCareResult dataImportant contributor
2010
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care
Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2010, 117: 180-189. PMID: 20939011, DOI: 10.1002/cncr.25542.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBlack PeopleBreast NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyEthnicityFemaleHealthcare DisparitiesHispanic or LatinoHormonesHumansInsurance CoverageInsurance, HealthMastectomyRacial GroupsRadiotherapy, AdjuvantSocial ClassSocioeconomic FactorsWhite PeopleConceptsDefinitive locoregional therapyHormone receptor testingArea-level socioeconomic statusBreast cancer careRace/ethnicityHormonal therapyLocoregional therapyReceptor testingSocioeconomic statusCancer careHispanic womenAdjuvant hormonal therapyAdjuvant systemic therapyInvasive breast cancerBreast cancer patientsMultivariate logistic regressionBreast cancer treatmentReceipt of careEligible patientsSystemic therapyBlack raceCancer patientsInsurance statusNational cohortBreast cancerInternational Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? Journal Of The National Cancer Institute 2010, 102: 456-463. PMID: 20220104, PMCID: PMC3298957, DOI: 10.1093/jnci/djq029.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBreast NeoplasmsCatheter AblationChemotherapy, AdjuvantClinical Trials as TopicCongresses as TopicConsensus Development Conferences as TopicDose-Response Relationship, DrugEarly Detection of CancerEuropeFemaleGene Expression ProfilingHumansImmunosuppressive AgentsInterdisciplinary CommunicationInternational CooperationLiver NeoplasmsLung NeoplasmsNeoplasm StagingNeoplastic Cells, CirculatingObserver VariationPatient Care TeamPatient SelectionPractice Guidelines as TopicRadiotherapy, AdjuvantSurvival RateConceptsMetastatic breast cancerOligometastatic diseaseBreast cancerMetastatic lesionsPrimary tumorEuropean Breast Cancer ConferenceFirst consensus recommendationsOptimal local treatmentRapid disease controlAvailable therapeutic optionsSubset of patientsLong-term outcomesLarge retrospective seriesDetectable metastatic lesionsAttractive therapeutic strategyChemotherapy optionsSurvival benefitSystemic therapyTreatment guidelinesRegional chemotherapyRetrospective seriesTask ForceLung metastasesTherapeutic optionsPatient population
2009
Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women
Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Research And Treatment 2009, 121: 743-751. PMID: 19949856, DOI: 10.1007/s10549-009-0643-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesEarly DiagnosisEmigrants and ImmigrantsFemaleHealth Services AccessibilityHealth Status DisparitiesHispanic or LatinoHumansLogistic ModelsMastectomy, SegmentalMiddle AgedMultivariate AnalysisRadiotherapy, AdjuvantResidence CharacteristicsRisk FactorsUnited StatesConceptsBreast cancerHispanic womenBreast cancer diagnosisRace/ethnicityPrimary therapyWhite womenStage I breast cancerNon-Hispanic white womenCancer diagnosisEarly-stage diseaseI breast cancerInvasive breast cancerAssociation of ethnicityForeign-born HispanicsInfluence of birthplaceTherapy differsTumor characteristicsSEER areasFirst diagnosisRates of stageAdjusted ratesMultinomial logistic regressionStage IAdvanced stageAppropriate interventions
2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
Kimmick G, Cirrincione C, Duggan D, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson I, Hudis C, Winer E, On Behalf of the Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Research And Treatment 2008, 113: 479-490. PMID: 18306034, PMCID: PMC4217205, DOI: 10.1007/s10549-008-9943-2.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDisease ProgressionDoxorubicinFemaleFluorouracilFollow-Up StudiesHumansMastectomyMethotrexateMiddle AgedNeoadjuvant TherapyNeoplasm StagingRadiotherapy, AdjuvantSurvival AnalysisConceptsStage III breast cancerBreast cancerNeoadjuvant doxorubicinClinical responseLymph nodesClinical stage III breast cancerAdequate organ functionClinical response rateComplete clinical responseInvolved lymph nodesPositive lymph nodesAdvanced breast cancerPathologic complete responsePhase II trialHazard of deathLong-term resultsLong-term survivalAdjuvant chemotherapyAdjuvant cyclophosphamideMedian followII trialNeoadjuvant treatmentMultimodality treatmentOverall survivalComplete responsePreoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions
Gralow JR, Zujewski JA, Winer E. Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions. Journal Of Clinical Oncology 2008, 26: 696-697. PMID: 18258975, DOI: 10.1200/jco.2007.15.9459.Peer-Reviewed Original Research
2007
Local Therapy and Survival in Breast Cancer
Punglia RS, Morrow M, Winer EP, Harris JR. Local Therapy and Survival in Breast Cancer. New England Journal Of Medicine 2007, 356: 2399-2405. PMID: 17554121, DOI: 10.1056/nejmra065241.Peer-Reviewed Original Research
2006
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, _ _. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. PMID: 16507275, DOI: 10.6004/jnccn.2006.2001.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkBreast cancer treatment guidelinesCancer treatment guidelinesAdjuvant therapyBreast cancerTreatment guidelinesAdjuvant therapy recommendationsQuantitative estrogen receptorComprehensive Cancer NetworkEstrogen receptor levelsPositive breast cancerEndocrine therapyPostmenopausal womenMenopausal statusTask ForcePredictive factorsGuideline panelHER2 statusBiologic markersAromatase inhibitorsTherapy recommendationsReceptor levelsEstrogen receptorHER2/Cancer Network
2005
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 64: 496-504. PMID: 16243442, DOI: 10.1016/j.ijrobp.2005.07.975.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFeasibility StudiesFemaleHumansPaclitaxelProspective StudiesRadiation PneumonitisRadiation-Sensitizing AgentsRadiotherapy DosageRadiotherapy, AdjuvantConceptsRadiation therapyBreast cancerAdjuvant doxorubicinConcurrent paclitaxelWeekly paclitaxelAC chemotherapyConcurrent radiationConcurrent treatmentGrade 2 radiation pneumonitisStage IIEarly-stage breast cancerAdjuvant AC chemotherapyDefinitive breast surgeryOperable stage IIWeekly paclitaxel treatmentConcurrent radiation therapyDose-limiting toxicityProtocol-based treatmentAdjuvant chemotherapyPaclitaxel scheduleSteroid therapyCyclophosphamide chemotherapyRadiation pneumonitisPulmonary injuryRadiation dermatitisBreast cancer.
Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network 2005, 3: 238-89. PMID: 16002000, DOI: 10.6004/jnccn.2005.0015.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsCombined Modality TherapyFemaleHumansMammographyMastectomyNeoplasm StagingRadiotherapy, Adjuvant